Cleveland Clinic Researchers and the Resverlogix Clinical Steering Committee Announce the ASSURE Trial Advancement
TSX Exchange Symbol: RVX
CALGARY, Dec. 13 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that Dr. Eldon R. Smith OC, MD, FRCPC, FCAHS, FAHA, FIACS has been appointed to the Company's Board of Directors. The Board remains at 6 members.
From 1992 to 1997, Dr. Smith was Dean of the Faculty of Medicine at the University of Calgary. From 1997 until 2010, he has been Editor-in-Chief of the Canadian Journal of Cardiology. Dr. Smith's research interests include circulatory mechanics, exercise physiology and echocardiography. He has published more than 250 papers and book chapters and has been a contributor to many national and international organizations; he has been President of the Canadian Cardiovascular Society and the Association of Canadian Medical Colleges and Vice President of the Inter-American Society of Cardiology. He has served on a number of public boards including the Alberta Heritage Foundation for Medical Research, the Alberta Health Professions Advisory Board, and the Premier's Advisory Council on Health in Alberta. He founded and served as President and Director of the Peter Lougheed Medical Research Foundation, a national initiative to support excellence in health research in Canada. He is chair of the Advisory Board of the Libin Cardiovascular Institute of Alberta and from 2006 to 2010 he was appointed by the Federal Government to chair the development of a National Strategy for Cardiovascular Health and Disease.
Resverlogix's Board of Directors remains at 6 members as Dr. William Cochrane will be stepping down from the Board effective today. Dr. Cochrane has been on the Board since its inception and has been a very important contributor to the growth and development of Resverlogix. The Board expresses its gratitude to Dr. Cochrane for his years of contributions. Current Board member, Dr. Peter Johann, has been appointed as Dr. Cochrane's replacement as Chairman of the Board. Dr. Johann is a Managing General Partner of NGN Capital. He was formerly the Division Head of Corporate Development for Boehringer Ingelheim and was Global Business Leader at F. Hoffman-La Roche.
Also announced today, Cleveland Clinic Researchers in combination with Resverlogix and the Clinical Steering Committee will advance the ASSURE IVUS study with unanimous approval. The committee consists of Dr. Steven Nissen, Dr. John Kastelein, Dr. Christie Ballantyne, Dr. Phil Barter and Dr. Stephen Nicholls.
In the upcoming Phase IIb multi-center, double-blinded, randomized "ApoA-I Synthesis Stimulation in Coronary Patients" (ASSURE) trial, researchers will test approximately 350 patients using a placebo-control arm for the assessment of coronary plaque changes with RVX-208 over a six month period, as determined by intravascular ultrasound.
"Attempts at plaque-reducing medications have largely focused on increasing HDL cholesterol levels because of HDL's ability to remove plaque and prevent plaque formation," said Stephen J. Nicholls, M.B.B.S., Ph.D., Principal Investigator of the upcoming ASSURE trial and Cardiovascular Director of the Cleveland Clinic Coordinating Center for Clinical Research. "However, enhancing ApoA-I synthesis would represent a significant paradigm change, in which the target is functional quality - rather than quantity - of HDL.
The six month ASSURE trial should benefit from these key changes based from the fact that ApoA-I, HDL and large HDL particles continued to increase throughout the ASSERT trial suggesting that peak pharmacologic effects had not yet been fully achieved at three months. The safety profile of the drug also suggested it was well within acceptable limits to allow for the advancement of the ASSURE trial. No evidence of liver damage was seen in the ASSERT trial thus allowing the ASSURE trial to move forward. Trial timing and enrollment details will be confirmed in H1, 2011 and further trial design updates and progress will be posted on www.Clinicaltrials.gov.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus to develop novel small molecules that enhance ApoA-1. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the July 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
For further information: For further information: